CD2665|cas:170355-78-9|西域试剂

CD2665,99.0%

产品编号：Bellancom-107437| CAS NO：170355-78-9| 分子式：C₃₁H₃₄O₅| 分子量：486.60

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-107437		￥1800.00	杭州北京（现货）
Bellancom-107437		￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CD2665

产品介绍

CD2665 是一种能口服的选择性 RAR-β,γ 拮抗剂，对 RAR-β 和 RAR-γ 作用的 K_d 值分别为 306 nM，110 nM。CD2665 与 RAR-α 处无结合。

生物活性

CD2665 is an orally active and selective RAR-β,γ antagonist, with K_d values of 306 nM, 110 nM for RAR-β and RAR-γ, repectively.

体外研究

CD2665 (100 nM; 9 days; 3T3 cells) has significant effects on cell growth and differentiation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	3T3 cells
Concentration:	100 nM
Incubation Time:	9 days
Result:	Abrogated the antiprolferative effects of ATRA , CD271 (adapalene, an RAR-β,γ agonist), and CD2043 (RAR-α,β,γ pan-agonist) returning cell numbers and percent LFCS to control level.

体内研究
(In Vivo)

CD2665 (0.6 mg/kg; Subcutaneous injection; daily, for 22 days) completely inhibits the overexpression of RARβ mRNA in the brain of alcohol treated mice.
CD2665 is a selective retinoid antagonist and elicits the expected maturation delay and growth plate expansion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice submitted to 10 months of ethanol consumption.
Dosage:	0.6 mg/kg
Administration:	Subcutaneous injection; daily, for 22 days.
Result:	Decreased brain RARβ mRNA levels (50% relative to control), without any change in RXR β/γ mRNA levels.

Animal Model:	Male and female mice (3 weeks).
Dosage:	1.6 mg/kg
Administration:	Oral gavage/intragastric; daily, for 31 days.
Result:	Growth plate closure had largely been prevented in LDE225/antagonist co-treated mice compared with those receiving LDE225 only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice submitted to 10 months of ethanol consumption.
Dosage:	0.6 mg/kg
Administration:	Subcutaneous injection; daily, for 22 days.
Result:	Decreased brain RARβ mRNA levels (50% relative to control), without any change in RXR β/γ mRNA levels.

Animal Model:	Male and female mice (3 weeks).
Dosage:	1.6 mg/kg
Administration:	Oral gavage/intragastric; daily, for 31 days.
Result:	Growth plate closure had largely been prevented in LDE225/antagonist co-treated mice compared with those receiving LDE225 only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice submitted to 10 months of ethanol consumption.
Dosage:	0.6 mg/kg
Administration:	Subcutaneous injection; daily, for 22 days.
Result:	Decreased brain RARβ mRNA levels (50% relative to control), without any change in RXR β/γ mRNA levels.

Animal Model:	Male and female mice (3 weeks).
Dosage:	1.6 mg/kg
Administration:	Oral gavage/intragastric; daily, for 31 days.
Result:	Growth plate closure had largely been prevented in LDE225/antagonist co-treated mice compared with those receiving LDE225 only.